Nutrilinea Invests in Apharm to Strengthen R&D and Concentrate on Product Innovation

Nutrilinea Invests in Apharm to Strengthen R&D and Concentrate on Product Innovation

The operation accelerates Apharm development and envisages seamless continuity with the founding family as an Apharm minority shareholder.


Milan, June 6, 2019 – Dietary supplement market leader Nutrilinea announces its merge with Apharm.

The Nutrilinea-Apharm partnership is set to become a key European player in the production and development of nutraceutical products. This collaboration combines Nutrilinea’s high-quality production standards and operational flexibility with Apharm’s innovation capacity.

Over the years, Apharm has become a reference point in the dietary supplement and medical device market. The company relies on the intellectual property of over 10 patent families, especially that of gastrointestinal and orthopedic therapy with approximately 40 globally registered trademarks.

Apharm Founders, Angelo and Paolo Pizzoni, will maintain a 30% stake in the share capital. They will keep working for the company on the Board of Directors with responsibility for strategic development and product and commercial innovation. Nutrilinea’s CEO, Maurizio Castorina, will serve as the company’s Managing Director.

Angelo and Paolo Pizzoni commented: “Important achievements to date indicate that the company objectives and management remain constant. We believe that Nutrilinea is the ideal partner in supporting Apharm’s new growth and development phase. Our commitment as managers and shareholders is unwavering and guarantees the company’s future. The company aspires to assert itself even more in the integrator and medical device arena.”

Maurizio Castorina, Nutrilinea CEO, added: “Apharm is a top Italian entrepreneurial excellence and an internationally recognized leader in the development of nutraceutical products and medical devices. Its market is defined by relevant long-term growth prospects worldwide. Apharm’s successful business model and constant commitment to research and innovation make it a unique reality in its target market. We aim to further support Angelo and Paolo Pizzoni and accelerate the growth of the Nutrilinea Group internationally by concentrating on new product development. The Apharm partnership allows us to synergistically enhance R&D. We can offer our customers the option to develop new dossiers and innovative formulations aligned to market demands”.

Giovannelli and Partners Law Office with Lawyers Matteo Delucchi, Beatrice Riva, and Matteo Bruni guided Nutrilinea in this operation. Marco Bastasin and Luca Bosco from Deloitte managed financial and tax due diligence.

Raffaelli Segreti Law Office assisted Apharm members through the following team: Andrea Raffaelli and Valentina Di Cesare of Sala; Noro and Partners with Stefano Noro handling tax and accounting; Fausto Rinallo, Giorgio Carere, and Nicoletta Rabiolo of Ethica Corporate Finance serving as financial advisor.